Briracetam composition, oral liquid and preparation method thereof
A brivaracetam composition with specific excipients addresses bitterness and stability issues, ensuring stable and effective oral solutions by using sodium carboxymethyl cellulose and hydroxypropyl methylcellulose, along with sodium citrate and anhydrous citric acid, to enhance taste and maintain drug stability.
Patent Information
- Application Number
- CN202411132325.5
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-19
- Publication Date
- 2024-12-06
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
Brivaracetam oral solutions suffer from bitterness, poor stability, and color changes during long-term storage, which affect their efficacy.
A brivaracetam composition comprising specific ratios of brivaracetam, organic solvent, thickener, pH regulator, and optional preservatives and flavoring agents, including sodium carboxymethyl cellulose and hydroxypropyl methylcellulose, is formulated to improve taste and stability, with sodium citrate and anhydrous citric acid enhancing stability.
The composition results in a brivaracetam oral solution with improved taste, controlled impurity content, and no significant color change over six months, maintaining drug efficacy.
Smart Images

Figure SMS_1 
Figure SMS_2 
Figure SMS_3
Abstract
Description
Technical Field
[0001] The present application relates to a brivaracetam composition, an oral solution and a preparation method thereof, and belongs to the field of medical technology. Background Art
[0002] Brivaracetam is a third-generation anti-epileptic drug and a structural analog of the anti-epileptic drug levetiracetam. It is indicated as an adjunctive treatment for partial-onset epilepsy in patients aged 16 years and older with epilepsy. Brivaracetam oral solution is a convenient dosage form, especially suitable for patients who have difficulty swallowing tablets or capsules, such as children, the elderly or patients with dysphagia. This dosage form allows for more flexible dosage adjustments to suit the needs of patients of different weights and ages.
[0003] However, brivaracetam tastes bitter and the stability of brivaracetam oral solution is poor. After being stored for a long time, the color of the brivaracetam oral solution changes and the impurity content increases, which reduces the efficacy of the brivaracetam oral solution. Summary of the invention
[0004] According to one aspect of the present application, a brivaracetam composition is provided, and the oral liquid prepared therefrom has a moderate taste, good stability, no color change problem after long-term storage, and controllable impurity content.
[0005] The brivaracetam composition described in the present application comprises, by weight, 5-15 parts of brivaracetam, 140-170 parts of an organic solvent, 1-5 parts of a thickener, and 2-5 parts of a pH regulator;
[0006] The thickener is a cellulose thickener.
[0007] Specifically, in parts by weight, the brivaracetam composition includes 10 parts of brivaracetam, 158 parts of an organic solvent, 3 parts of a thickener, and 4.15 parts of a pH adjuster.
[0008] Optionally, the cellulose thickener is selected from any one or more of carboxymethyl cellulose, sodium carboxymethyl cellulose, hydroxyethyl cellulose, hydroxypropyl cellulose, and hydroxypropyl methyl cellulose.
[0009] Optionally, the hydroxypropyl methylcellulose has a methoxy content of 27-30 wt %.
[0010] Optionally, the cellulose thickener includes sodium carboxymethyl cellulose.
[0011] Optionally, the cellulose thickener further includes hydroxypropyl methylcellulose.
[0012] Optionally, the weight ratio of the hydroxypropyl methylcellulose to sodium carboxymethylcellulose is (1-2):1; optionally, the weight ratio of the hydroxypropyl methylcellulose to sodium carboxymethylcellulose is 1.5:1.
[0013] Optionally, the brivaracetam composition further comprises 0.5-1.8 parts by weight of a preservative; preferably, the brivaracetam composition further comprises 1.1 parts of a preservative.
[0014] Optionally, the preservatives are propylparaben and methylparaben.
[0015] Optionally, the weight ratio of propylparaben to methylparaben is (2-3):1; preferably, the weight ratio of propylparaben to methylparaben is 2.7:1.
[0016] Optionally, the organic solvent is an alcohol solvent.
[0017] Optionally, the alcohol solvent includes glycerol.
[0018] Optionally, the pH adjuster is sodium citrate and anhydrous citric acid.
[0019] Optionally, the weight ratio of the sodium citrate to anhydrous citric acid is (2.5-3.5):(0.8-1.3); preferably, the weight ratio of the sodium citrate to anhydrous citric acid is 3.05:1.1.
[0020] Optionally, the brivaracetam composition further comprises 0.1-10 parts by weight of a flavoring agent; preferably, the brivaracetam composition further comprises 5-6 parts by weight of a flavoring agent.
[0021] Specifically, the brivaracetam composition further comprises 5.5 parts by weight of flavoring agent.
[0022] The flavoring agent described in the present application is not particularly limited and can be routinely selected by those skilled in the art.
[0023] Optionally, the flavoring agent is acesulfame potassium and / or red plum essence.
[0024] The second aspect of the present application provides a brivaracetam oral solution, comprising the brivaracetam composition.
[0025] Optionally, the brivaracetam oral solution comprises 145-210 parts of brivaracetam composition and 1150 parts of purified water, by weight.
[0026] Specifically, in parts by weight, the brivaracetam oral solution comprises 181.75 parts of brivaracetam composition and 1150 parts of purified water.
[0027] In another aspect, the present application provides a method for preparing the brivaracetam oral solution, comprising the following steps:
[0028] (1) Preparation of solution 1: Mixture I including a thickener and 50-60 wt % of an organic solvent is mixed with 5-10 wt % of purified water and stirred to obtain solution 1;
[0029] (2) Preparation of solution 2: Stirring a mixture II including 40-50 wt % purified water, a pH adjuster, brivaracetam, and the remaining organic solvent to obtain solution 2;
[0030] (3) Solution 1, solution 2 and the remaining purified water are mixed, stirred, and filtered to obtain brivaracetam oral solution.
[0031] Optionally, the mixture II further comprises a preservative and / or a flavoring agent.
[0032] Optionally, the preparation method of the brivaracetam oral solution comprises the following steps:
[0033] (1) Preparation of solution 1: a mixture including a thickener and 50-60 wt % of an organic solvent is mixed with 5-10 wt % of purified water, and stirred to obtain solution 1;
[0034] (2) Preparation of Solution 2: 40-50 wt % purified water, preservative, pH adjuster, acesulfame potassium, brivaracetam, and remaining organic solvent are mixed and stirred to obtain an intermediate solution, and the intermediate solution and red plum essence are mixed and stirred to obtain Solution 2;
[0035] (3) Solution 1, solution 2 and the remaining purified water are mixed, stirred, and filtered to obtain brivaracetam oral solution.
[0036] The beneficial effects of this application include:
[0037] 1. In the present application, the methoxy content of hydroxypropyl methylcellulose is controlled to be 27-30wt%, and the viscosity of the finally obtained brivaracetam oral solution is 49.0mPa.s, which complements sodium carboxymethyl cellulose, reduces the amount of thickener, avoids the uneven mixing between the substances caused by the cellulose thickener, and avoids the excessive pressure of the later canning caused by excessive viscosity.
[0038] In addition, the present application uses sodium carboxymethyl cellulose and hydroxypropyl methylcellulose to promote the stability of various items, can control the impurities at a lower content, and maintain the stability of the drug efficacy.
[0039] 2. The present application uses a combination of methylparaben and propylparaben, in combination with sodium carboxymethylcellulose and hydroxypropyl methylcellulose, and unexpectedly found that the stability of the oral solution of brivaracetam was prolonged, accelerating the color to no significant change within 6 months, which may be due to the promotion and stabilization of the buffering effect of sodium citrate and anhydrous citric acid, or the stability of the overall combination of excipients and original drug ingredients. DETAILED DESCRIPTION
[0040] The present application is described in detail below with reference to embodiments, but the present application is not limited to these embodiments.
[0041] Unless otherwise specified, the raw materials in the examples of this application were purchased through commercial channels.
[0042] Example 1
[0043] Brivaracetam oral solution, each milliliter of oral solution contains the following ingredients:
[0044]
[0045] The preparation method of brivaracetam oral liquid preparation is as follows:
[0046] (1) Preparation of solution 1: a mixture including sodium carboxymethylcellulose, hydroxypropyl methylcellulose and 55 wt % glycerol is mixed with 8 wt % purified water and stirred to obtain solution 1;
[0047] (2) Preparation of Solution 2: 45 wt % purified water, methylparaben, propylparaben, sodium citrate, anhydrous citric acid, acesulfame potassium, brivaracetam, and the remaining glycerin were mixed and stirred to obtain an intermediate solution, and the intermediate solution was mixed with red plum essence and stirred to obtain Solution 2;
[0048] (3) Solution 1, solution 2 and the remaining purified water are mixed, stirred, and filtered to obtain brivaracetam oral solution.
[0049] Example 2
[0050] Example 2 provides a brivaracetam oral solution, and the specific implementation method is the same as that of Example 1. By adjusting the content of sodium citrate and anhydrous citric acid, the pH is controlled to be 4.5, 5.0, 5.5, 6.0, and 6.5, respectively.
[0051] The specific implementation method of the preparation method of the brivaracetam oral solution is the same as that of Example 1.
[0052] Comparative Example 1
[0053] Comparative Example 1 provides a brivaracetam oral solution, and the specific implementation manner is the same as that of Example 1, except that sodium carboxymethyl cellulose is absent.
[0054] The specific implementation method of the brivaracetam oral solution is the same as that of Example 1, except that sodium carboxymethyl cellulose is not added.
[0055] Comparative Example 2
[0056] Comparative Example 2 provides a brivaracetam oral solution, the specific implementation manner is the same as Example 1, except that hydroxypropyl methylcellulose is absent.
[0057] The specific implementation method of the brivaracetam oral solution is the same as that of Example 1, except that hydroxypropyl methylcellulose is not added.
[0058] Comparative Example 3
[0059] Comparative Example 3 provides a brivaracetam oral solution, and the specific implementation manner is the same as that of Example 1, except that the methoxy content of hydroxypropyl methylcellulose is 19-24wt%.
[0060] The specific implementation method of the preparation method of the brivaracetam oral solution is the same as that of Example 1.
[0061] Comparative Example 4
[0062] Comparative Example 4 provides a brivaracetam oral solution, the specific implementation manner is the same as that of Example 1, except that methylparaben is absent.
[0063] The specific implementation method of the brivaracetam oral solution is the same as that of Example 1, except that methylparaben is not added.
[0064] Comparative Example 5
[0065] Comparative Example 5 provides a brivaracetam oral solution, the specific implementation manner is the same as Example 1, except that propylparaben is absent.
[0066] The specific implementation method of the brivaracetam oral solution is the same as that of Example 1, except that propylparaben is not added.
[0067] Comparative Example 6
[0068] Comparative Example 6 provides a brivaracetam oral solution, the specific implementation manner is the same as Example 1, except that propylparaben is replaced by potassium sorbate.
[0069] The specific implementation method of the preparation method of the brivaracetam oral solution is the same as that of Example 1.
[0070] The compatibility of the raw materials and excipients in Example 1 was studied. It was sealed in a 300ml brown soda-lime glass bottle. It was placed at a high temperature of 50°C, exposed to light, and exposed to light with packaging for 10 days and 30 days. The compatibility of the raw and excipients of this product was investigated in an N-1 manner, with properties, clarity and color, pH value, related substance I, related substance II, isomers, content, and methylparaben content as indicators. The test results are shown in Table 1. The detection refers to the general rules of the fourth part of the Chinese Pharmacopoeia 2020 edition 0512. Among them, the test conditions for related substances: mobile phase A: 0.1% phosphoric acid aqueous solution; mobile phase B: acetonitrile, chromatographic column: Waters XBridge C18; detection wavelength is 210nm; mobile phase flow rate is 1.0ml / min; column temperature is 40°C; elution gradient is as follows:
[0071]
[0072] Table 1
[0073]
[0074]
[0075] It can be seen from the test results in Table 1 that there is no significant difference in the stability period of the oral solution of the present application, indicating that the compatibility is good under the types and proportions of raw and auxiliary materials of the present application.
[0076] The stability of Example 2 was investigated, and the results are shown in Table 2.
[0077] Table 2
[0078]
[0079] From the test results in Table 2, it can be seen that the isomers, content and impurities of the brivaracetam oral solution of the present application are within a reasonable range within a pH range of 4.5-6.5, and the quality is stable within a wider pH range.
[0080] The stability test of the brivaracetam oral solution obtained in Example 1 was carried out under the following test conditions: 60°C, naked exposure to light (5000 lx), and accelerated (40°C / 75% RH). The test was carried out in accordance with the General Rules 0512 of the Fourth Part of the 2020 Edition of the Chinese Pharmacopoeia, and the test results are shown in Table 3.
[0081] Table 3
[0082]
[0083] The brivaracetam oral solution obtained in the examples and comparative examples was accelerated (40°C / 75%RH) for 6 months, and the color change of the appearance was recorded. The results are shown in Table 4.
[0084] Table 4
[0085]
[0086]
[0087] Five people were recruited to test the taste of Example 1 and the reference preparation. The test results are shown in Table 5 below.
[0088] Table 5
[0089] Reference preparation Example 1 Smell level Heavy Moderate Sweetness Heavy Moderate Bitterness Heavy Moderate
[0090] The above are only a few embodiments of the present application and do not constitute any form of limitation to the present application. Although the present application is disclosed as above with preferred embodiments, it is not intended to limit the present application. Any technician familiar with the profession, without departing from the scope of the technical solution of the present application, using the technical content disclosed above to make slight changes or modifications are equivalent to equivalent implementation cases and fall within the scope of the technical solution.
Claims
1. A brivaracetam composition, It is characterized in that In parts by weight, it comprises 5-15 parts of brivaracetam, 140-170 parts of an organic solvent, 1-5 parts of a thickener, and 2-5 parts of a pH regulator; The thickener is a cellulose thickener.
2. The brivaracetam composition according to claim 1, It is characterized in that The cellulose thickener is selected from any one or more of carboxymethyl cellulose, sodium carboxymethyl cellulose, hydroxyethyl cellulose, hydroxypropyl cellulose and hydroxypropyl methyl cellulose.
3. The brivaracetam composition according to claim 2, It is characterized in that The cellulose thickener includes sodium carboxymethyl cellulose; Preferably, the cellulose thickener further comprises hydroxypropyl methylcellulose.
4. The brivaracetam composition according to claim 3, It is characterized in that The weight ratio of the hydroxypropyl methylcellulose to sodium carboxymethyl cellulose is (1-2):
1.
5. The brivaracetam composition according to any one of claims 1 to 4, It is characterized in that The brivaracetam composition further comprises 0.5-1.8 parts by weight of a preservative.
6. The brivaracetam composition according to claim 5, It is characterized in that The brivaracetam composition further comprises 0.1-10 parts by weight of a flavoring agent.
7. A brivaracetam oral solution, It is characterized in that The invention comprises the brivaracetam composition according to any one of claims 1 to 6.
8. The brivaracetam oral solution according to claim 7, It is characterized in that In parts by weight, the brivaracetam oral solution comprises 145-210 parts of brivaracetam composition and 1150 parts of purified water.
9. A method for preparing the brivaracetam oral solution according to claim 7 or 8, It is characterized in that The following steps are included: (1) Preparation of solution 1: Mixture I including a thickener and 50-60 wt % of an organic solvent is mixed with 5-10 wt % of purified water and stirred to obtain solution 1; (2) Preparation of solution 2: Stirring a mixture II including 40-50 wt % purified water, a pH adjuster, brivaracetam, and the remaining organic solvent to obtain solution 2; (3) Solution 1, solution 2 and the remaining purified water are mixed, stirred, and filtered to obtain brivaracetam oral solution.
10. The method for preparing the brivaracetam oral solution according to claim 9, It is characterized in that The mixture II may also include preservatives and / or flavoring agents.
Citation Information
Patent Citations
Brivaracetam oral solution and preparation method thereof
CN106491523A
Brivaracetam medicine solution and preparation method thereof
CN113908120A
Preparation and preparation method of brivaracetam oral liquid
CN116265011A
High-stability brivaracetam solution as well as preparation method and application thereof
CN116687843A
